These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 36516322)
1. Comparative Effects of 30 Antipsychotics on Risk of Catatonia: An Analysis of the WHO Pharmacovigilance Database. Da Costa J; Very E; Rousseau V; Virolle J; Redon M; Taïb S; Revet A; Montastruc F J Clin Psychiatry; 2022 Dec; 84(1):. PubMed ID: 36516322 [No Abstract] [Full Text] [Related]
2. What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review. Virolle J; Redon M; Montastruc F; Taïb S; Revet A; Zivkovic V; Da Costa J; Very E Schizophr Res; 2023 Dec; 262():184-200. PubMed ID: 37599139 [TBL] [Abstract][Full Text] [Related]
3. Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database. de Filippis R; Kane JM; Arzenton E; Moretti U; Raschi E; Trifirò G; Barbui C; De Fazio P; Gastaldon C; Schoretsanitis G Drug Saf; 2024 Aug; 47(8):745-757. PubMed ID: 38722481 [TBL] [Abstract][Full Text] [Related]
4. Drug-related catatonia in youths: real-world insights from the WHO Safety Database. Merino D; Gérard AO; Lavrut T; Askenazy F; Thümmler S; Montastruc F; Drici MD Eur Child Adolesc Psychiatry; 2024 May; 33(5):1383-1393. PubMed ID: 37308606 [TBL] [Abstract][Full Text] [Related]
5. First generation antipsychotic-associated serious adverse events in women: a retrospective analysis of a pharmacovigilance database. McCall KL; Doughty BJ; Piper BJ; Naik H; Bange S; Leppien EE Int J Clin Pharm; 2024 Apr; 46(2):515-521. PubMed ID: 38315306 [TBL] [Abstract][Full Text] [Related]
6. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. de Germay S; Montastruc F; Carvajal A; Lapeyre-Mestre M; Montastruc JL Parkinsonism Relat Disord; 2020 Jan; 70():55-59. PubMed ID: 31865063 [TBL] [Abstract][Full Text] [Related]
7. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]. Bret P; Bret MC; Queuille E Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381 [TBL] [Abstract][Full Text] [Related]
8. Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022. Storck W; de Laportalière TT; Yrondi A; Javelot H; Berna F; Montastruc F Psychopharmacology (Berl); 2024 Jun; 241(6):1205-1212. PubMed ID: 38376511 [TBL] [Abstract][Full Text] [Related]
9. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Meyer-Massetti C; Vaerini S; Rätz Bravo AE; Meier CR; Guglielmo BJ Int J Clin Pharm; 2011 Oct; 33(5):806-14. PubMed ID: 21809143 [TBL] [Abstract][Full Text] [Related]
10. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. O'Brien A Int J Geriatr Psychiatry; 2016 Jul; 31(7):683-93. PubMed ID: 26679687 [TBL] [Abstract][Full Text] [Related]
11. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Kishimoto T; Agarwal V; Kishi T; Leucht S; Kane JM; Correll CU Mol Psychiatry; 2013 Jan; 18(1):53-66. PubMed ID: 22124274 [TBL] [Abstract][Full Text] [Related]
13. Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase Kaguelidou F; Valtuille Z; Durrieu G; Delorme R; Peyre H; Treluyer JM; Montastruc F; Chouchana L Drug Saf; 2023 Jan; 46(1):77-85. PubMed ID: 36459374 [TBL] [Abstract][Full Text] [Related]
14. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists. Kwan ATH; Rosenblat JD; Mansur RB; Rhee TG; Teopiz K; Le GH; Wong S; Cao B; Ho R; McIntyre RS J Affect Disord; 2024 Oct; 363():589-594. PubMed ID: 39029700 [TBL] [Abstract][Full Text] [Related]
15. Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan. Misawa F; Fujii Y; Takeuchi H J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 35921512 [No Abstract] [Full Text] [Related]
16. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. Jackson JW; Schneeweiss S; VanderWeele TJ; Blacker D PLoS One; 2014; 9(8):e105376. PubMed ID: 25140533 [TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of the efficacy of second-generation antipsychotics. Davis JM; Chen N; Glick ID Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218 [TBL] [Abstract][Full Text] [Related]
18. Antipsychotics and risk of QT prolongation: a pharmacovigilance study. Bordet C; Garcia P; Salvo F; Touafchia A; Galinier M; Sommet A; Montastruc F Psychopharmacology (Berl); 2023 Jan; 240(1):199-202. PubMed ID: 36515735 [TBL] [Abstract][Full Text] [Related]
19. 'Real world' comparison of first- and second-generation antipsychotics in regard to length of inpatient hospitalization and number of re-hospitalizations. Advokat C; Hill BD; Comaty JE Psychiatr Q; 2008 Mar; 79(1):55-64. PubMed ID: 18060498 [TBL] [Abstract][Full Text] [Related]
20. Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: A retrospective cohort study. Fang SC; Huang CY; Liao DL; Hsu CC; Shao YJ Schizophr Res; 2019 Oct; 212():150-156. PubMed ID: 31395489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]